CSF2 and multiple sclerosis: Despite these issues, in light of recent developments testing anti-GM-CSF in clinical trials for the treatment of other inflammatory conditions such as multiple sclerosis (Constantinescu et al., 2015) it will be interesting to see if subgroups of patients with hyperinflammatory innate immune activation-driven IBD could benefit from GM-CSF blockade.